AWCI
SPRY icon

Alpine Woods Capital Investors’s ARS Pharmaceuticals SPRY Stock Holding History

Alpine Woods Capital Investors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$80.3K – 245
2026
Q1 		$80.3K Buy
+10,000
New +$95.8K 0.02% 199

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Alpine Woods Capital Investors's SPRY Position: Q2 2026 in Review

Alpine Woods Capital Investors sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 10,000 shares — an estimated $80.3K sold.

Alpine Woods Capital Investors first reported a position in SPRY in Q1 2026 and held it in 1 quarter. The position peaked at $80.3K in Q1 2026. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Alpine Woods Capital Investors reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Alpine Woods Capital Investors sold 10,000 ARS Pharmaceuticals shares in Q2 2026, an estimated $80.3K.
  • Alpine Woods Capital Investors first reported a position in ARS Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Alpine Woods Capital Investors's ARS Pharmaceuticals position peaked at $80.3K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Alpine Woods Capital Investors's 13F filing for Q2 2026, filed 7 Aug 2026.